THE FOUR COMPARED / 05
Which Compounds Were Tested in People?
One compound has large human studies. The other three rely mainly on cells, animals, or one tiny human safety test.
What is the clearest difference among the four?
Researchers made these compounds for different aims, then tested them in different ways. One “works” or “fails” line cannot fairly cover all four.
Semaglutide has approved uses and large human studies where chance chose the care. BPC-157 has many animal findings and a safety test in two people.
KPV has cell, mouse, and special-carrier work but no published human trial here. MOTS-c has mouse work and a small human blood study, without a benefit trial.
A cell test may suggest how a change starts. An animal test tells what happened there, while a human trial can test a cause that matters to you.
A finding of no change means more in a large, useful study. When no study exists, you have a missing answer, not proof of failure.
Who or what was tested for each compound?
| Question | BPC-157 | Semaglutide | KPV | MOTS-c |
|---|---|---|---|---|
| What did researchers hope to change? | hurt tissue and repair | GLP-1, a gut hormone that controls sugar and hunger | bowel swelling and drug delivery | cell damage, sugar use, and muscle work |
| What is the clearest lab finding? | a cell switch started new blood vessels [4] | GLP-1 changed insulin, stomach speed, and hunger | a bowel-cell gate let KPV enter and lower swelling signals [15] | cells turned on defenses; one enzyme changed muscle sugar use [18][22] |
| What is the strongest study here? | animal injuries and a tiny human safety test [1][5][6] | large human studies with care chosen by chance [9][10][11] | cell and mouse bowel studies [13][14][15][16] | lab and animal work plus a human blood study [18][19][21] |
| Is there a human benefit trial here? | No sound large trial [2] | Yes [9][10][11] | None | None |
| What remains unknown? | Human benefit and long-term safety | Who gains most, who can stay on it, and rare harm | Whether it reaches people, helps them, or causes harm | Whether the mouse and blood findings lead to human benefit |
| What does no change mean now? | Little beyond one short safety test | More when a large study asks one clear question | No human result because no human trial exists | No human result because no human trial exists |
Does an explanation from the lab prove a human benefit?
BPC-157 may spur new blood vessels that aid repair [4]. KPV may enter bowel cells through a natural gate and lower swelling signals [15].
MOTS-c helped cells defend themselves and changed an enzyme tied to muscle sugar use [18][22]. Semaglutide copies a gut hormone that affects blood sugar, stomach speed, and hunger.
These lab findings help researchers plan the next test. Only semaglutide also has several large human studies.
A possible reason for an effect does not tell how large the benefit will be. It also cannot show who may stop because of harm.
Blocking a cell step can show that the step caused one lab effect. It still cannot show whether a person feels or lives better.
Why does “no effect” depend on the study?
Semaglutide lost an average weight-loss match against tirzepatide [8]. Semaglutide still reduced weight, but tirzepatide reduced more in that study.
SELECT and FLOW asked clear health questions in large groups [9][10]. A quiet result there can rule out more than one from a tiny test.
BPC-157 offers the reverse problem because its safety test had only two people [1]. No harm appeared, yet rare harm could easily go unseen.
KPV and MOTS-c have no human trial here. Neither can be called safe or a failure in people when no people were tested.
Before trusting “no effect,” note how many people took part and for how long. Then ask whether the study measured something a person would notice.
How much is known about each compound’s safety?
Semaglutide commonly causes stomach and bowel trouble, with more gallbladder trouble and rare worries under study [12]. These facts come from formal studies where many people received the drug.
BPC-157 has far less human work. Its tiny test found no harm [1], while a review warned about scant research and poorly controlled sales [2].
KPV and MOTS-c have no human safety trial here. “No known side effects” hides the missing work; “human safety is unknown” tells the truth.
Product quality raises another question. BPC-157, KPV, and MOTS-c aren't approved medicines in these papers, so purity and cleanliness may vary.
KPV mouse studies often used special carriers [13][14]. A result from one exact carrier does not belong to free KPV or an unknown product.
What future studies would make the answers clearer?
BPC-157 needs repeat work, human handling tests, fair benefit studies, and long safety checks. KPV first needs one stable, well-made product for careful human tests.
MOTS-c needs larger human groups to see whether its blood link holds. Human testing would then start small, watching safety before testing benefit.
Semaglutide still needs longer follow-up and fair tests against other drugs. It also needs answers for people unlike those in the first large studies.
Research teams need to name the main result before starting and report every harm. Other teams can then repeat the work, including results that find nothing.
“Peptide” names a kind of compound, not a grade of proof. Trust grows only when human studies become larger, fairer, and longer.